Fortress Biotech, Inc.

Altı ay boyunca karlılık: +33.69%
Temettü getirisi: 14.81%
Sektör: Healthcare

9.02 $

0 $ 0%
5 $
9.47 $

paper.min_max_per_year

Promosyon programı Fortress Biotech, Inc.

Temel parametreler

IPO date
2017-11-14
ISIN
US34960Q2084
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
14.81
Дивиденд ао
0.585
Сайт

Seviye

Hafife alma
İsim Anlam Seviye
P/S 2.43 6
P/BV -85.36 0
P/E 0 0
Yeterlik
İsim Anlam Seviye
ROA -29.51 0
ROE -203.16 0
ROIC 0 0
Temettüler
İsim Anlam Seviye
Temettü getirisi 14.81 10
DSI 0.7857 7.86
Ortalama temettü büyümesi -25 0
Görev
İsim Anlam Seviye
Debt/EBITDA -0.727 10
Debt/Ratio 0.5267 9
Debt/Equity -88.73 10
Büyüme dürtüsü
İsim Anlam Seviye
Hasılat, % 26.48 4
Ebitda, % 12.36 2
EPS, % 41.86 6

paper.price.prices

Fiyat Common.min. Common.max. Değiştirmek paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 9.02 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 8.91 $ 0 $ 0 $ +1.28 % 0 % 0 %
common.calendar.number_days.30d 6.45 $ 0 $ 0 $ +39.91 % 0 % 0 %
common.calendar.number_days.90d 5.19 $ 6.15 $ 9.47 $ +73.87 % 0 % 0 %
common.calendar.number_days.180d 6.75 $ 5.08 $ 9.47 $ +33.69 % 0 % 0 %
common.calendar.number_days.1y 6.51 $ 5 $ 9.47 $ +38.62 % 0 % 0 %
common.calendar.number_days.3y 20 $ 5 $ 22 $ -54.88 % 0 % 0 %
common.calendar.number_days.5y 18.35 $ 5 $ 26.49 $ -50.82 % 0 % 0 %
common.calendar.number_days.10y 5 $ 5 $ 26.49 $ +180.48 % 0 % 0 %
common.calendar.number_days.ytd 6.8 $ 5.08 $ 9.47 $ +32.71 % 0 % 0 %

Ana sahipler

Benzer şirketler



Şirket yönetimi

Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Lindsay Allan Rosenwald Executive Chairman, President & CEO 212.66k 1955 (70 yıllar)
Mr. Michael S. Weiss Esq. Executive Vice Chairman of Strategic Development & Director 182.66k 1966 (59 yıllar)
Mr. David Jin CFO & Head of Corporate Development 407.33k 1990 (35 yıllar)
Dr. George C. Avgerinos Senior Vice President of Biologics Operations 386.49k 1954 (71 yıl)
Mr. Samuel Berry General Counsel & Corporate Secretary N/A

Şirket bilgileri

Adres: United States, Bay Harbor Islands. FL, 1111 Kane Concourse - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.fortressbiotech.com

Şirket hakkında Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.